Authors
Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Evidences regarding the efficacy of different antibiotic regimens proposed for treatment of
multidrug‑resistant (MDR) Gram‑negative pathogens have been reviewed. Available data in
Scopus, Medline, EMBASE, the Cochrane central register of controlled trials, and Cochrane
database of systematic reviews have been collected. Several antibiotic regimens are proposed
for treatment of MDR Gram‑negative infections (defined as nonsusceptibility to at least
one agent in three or more antimicrobial categories). The most challenging issue is the
treatment of carbapenem‑resistant (CR) Gram‑negative pathogens. A carbapenem plus either
colistin or tigecycline was the most effective regimen for treatment of CR Gram‑negative
pathogens with low‑level resistance (minimal inhibitory concentration [MIC] ≤ 8 mg/L).
However, in high‑level resistance (MIC > 8 mg/L), combination of colistin and tigecycline
showed promising effect.
Keywords
- Cloete TE. Resistance mechanisms of bacteria to antimicrobial
compounds. Int Biodeterior Biodegradation 2003;51:277‑82.
2. Tenover FC. Mechanisms of antimicrobial resistance in
bacteria. Am J Med 2006;119:S3‑10.
3. Rice LB. Federal funding for the study of antimicrobial
resistance in nosocomial pathogens: No ESKAPE. J Infect Dis
2008;197:1079‑81.
4. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination
therapy for carbapenem‑resistant Gram‑negative bacteria.
Expert Rev Anti Infect Ther 2013;11:1333‑53.
5. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC.
Multidrug‑resistant Pseudomonas aeruginosa and Acinetobacter
baumannii: Resistance mechanisms and implications for
therapy. Expert Rev Anti Infect Ther 2010;8:71‑93.
6. Livermore DM, Woodford N. Carbapenemases: A problem in
waiting? Curr Opin Microbiol 2000;3:489‑95.
7. Clatworthy AE, Pierson E, Hung DT. Targeting virulence:
A new paradigm for antimicrobial therapy. Nat Chem Biol
2007;3:541‑8.
8. Queenan AM, Bush K. Carbapenemases: The versatile
beta‑lactamases. Clin Microbiol Rev 2007;20:440‑58.
9. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the
antibiotic resistance crisis. Curr Opin Pharmacol 2014;18:56‑60.
10. Paterson DL. Resistance in gram‑negative bacteria:
Enterobacteriaceae. Am J Infect Control 2006;34:S20‑8.
11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y,
Falagas ME, Giske CG, et al. Multidrug‑resistant, extensively
drug‑resistant and pandrug‑resistant bacteria: An international
expert proposal for interim standard definitions for acquired
resistance. Clin Microbiol Infect 2012;18:268‑81.
12. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME.
Carbapenems versus alternative antibiotics for the
treatment of bacteraemia due to Enterobacteriaceae producing
extended‑spectrum ß‑lactamases: A systematic review and
meta‑analysis. J Antimicrob Chemother 2012;67:2793‑803.
13. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ.
Deaths attributable to carbapenem‑resistant Enterobacteriaceae
infections. Emerg Infect Dis 2014;20:1170‑5.
14. Maragakis LL, PerlTM. Acinetobacter baumannii: Epidemiology,
antimicrobial resistance, and treatment options. Clin Infect Dis
2008;46:1254‑63.
15. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS,
Arruda EA, et al. Intravenous colistin as therapy for
nosocomial infections caused by multidrug‑resistant
Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect
Dis 1999;28:1008‑11.
16. SobieszczykME, FuruyaEY, HayCM, PancholiP, Della‑LattaP,
Hammer SM, et al. Combination therapy with polymyxin B
for the treatment of multidrug‑resistant Gram‑negative
respiratory tract infections. J Antimicrob Chemother
2004;54:566‑9.
17. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G,
Sermaides GJ, Falagas ME. Combination therapy with
intravenous colistin for management of infections due to
multidrug‑resistant Gram‑negative bacteria in patients
without cystic fibrosis. Antimicrob Agents Chemother
2005;49:3136‑46.
18. Saballs M, Pujol M, Tubau F, Peña C, Montero A,
Domínguez MA, et al. Rifampicin/imipenem combination in
the treatment of carbapenem‑resistant Acinetobacter baumannii
infections. J Antimicrob Chemother 2006;58:697‑700.
19. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC.
Prognosis of adult patients with bacteremia caused by
extensively resistant Acinetobacter baumannii. Diagn Microbiol
Infect Dis 2007;59:181‑90.
20. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS.
Ampicillin/sulbactam compared with polymyxins for the
treatment of infections caused by carbapenem‑resistant
Acinetobacter spp. J Antimicrob Chemother 2008;61:1369‑75.
21. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G,
Damala M, Falagas ME. Intravenous fosfomycin for
the treatment of nosocomial infections caused by
carbapenem‑resistant Klebsiella pneumoniae in critically
ill patients: A prospective evaluation. Clin Microbiol Infect
2010;16:184‑6.
22. GoundenR, Bamford C, van Zyl‑SmitR, Cohen K, Maartens G.
Safety and effectiveness of colistin compared with tobramycin
for multi‑drug resistant Acinetobacter baumannii infections.
BMC Infect Dis 2009;9:26.
23. Tsioutis C, Kritsotakis EI, Maraki S, Gikas A. Infections by
pandrug‑resistant gram‑negative bacteria: Clinical profile,
therapeutic management, and outcome in a series of
21 patients. Eur J Clin Microbiol Infect Dis 2010;29:301‑5.
24. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML,
Coppolecchia S, et al. High‑dose, extended‑interval colistin
administration in critically ill patients: Is this the right dosing
strategy? A preliminary study. Clin Infect Dis 2012;54:1720‑6.
25. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P,
Leonildi A, et al. Carbapenem‑sparing antibiotic
regimens for infections caused by Klebsiella pneumoniae
carbapenemase‑producing K. pneumoniae in intensive care
unit. Clin Infect Dis 2013;56:697‑700.
26. Kontopidou F, Giamarellou H, Katerelos P, Maragos A,
Kioumis I, Trikka‑Graphakos E, et al. Infections caused by
carbapenem‑resistant Klebsiella pneumoniae among patients
in intensive care units in Greece: A multi‑centre study on
clinical outcome and therapeutic options. Clin Microbiol Infect
2014;20:O117‑23.
27. Balandin Moreno B, Fernández Simón I, Pintado García V,
Sánchez Romero I, Isidoro Fernández B, Romera
Ortega MA, et al. Tigecycline therapy for infections due to
carbapenemase‑producing Klebsiella pneumoniae in critically
ill patients. Scand J Infect Dis 2014;46:175‑80. - 28. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M,
Katsiari M, et al. Outcomes of critically ill intensive
care unit patients treated with fosfomycin for infections
due to pandrug‑resistant and extensively drug‑resistant
carbapenemase‑producing Gram‑negative bacteria. Int J
Antimicrob Agents 2014;43:52‑9.
29. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M,
Porath A, et al. Nosocomial multi‑drug resistant Acinetobacter
baumannii blood stream infection: Risk factors and outcome
with ampicillin‑sulbactam treatment. J Hosp Infect 2003;54:32‑8.
30. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY,et al.
Multidrug‑resistant Acinetobacter baumannii bacteraemia:
Clinical features, antimicrobial therapy and outcome. Clin
Microbiol Infect 2007;13:196‑8.
31. Choi JY, Kim CO, Park YS, Yoon HJ, Shin SY, Kim YK, et al.
Comparison of efficacy of cefoperazone/sulbactam and
imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Yonsei Med J 2006;47:63‑9.
32. Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E,
SkoutelisA, et al. Prospective observational study of the impact
of VIM‑1 metallo‑beta‑lactamase on the outcome of patients
with Klebsiella pneumoniae blood stream infections. Antimicrob
Agents Chemother 2009;53:1868‑73.
33. Lim SK, Lee SO, Choi SH, Choi JP, Kim SH, Jeong JY, et al. The
outcomes of using colistin for treating multidrug resistant
Acinetobacter species blood stream infections. J Korean Med
Sci 2011;26:325‑31.
34. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A,
Bonomo RA, et al. Treatment and outcomes in
carbapenem‑resistant Klebsiella pneumoniae blood stream
infections. Diagn Microbiol Infect Dis 2011;69:357‑62.
35. Tumbarello M, Viale P, Viscoli C, Trecarichi EM,
Tumietto F, Marchese A, et al. Predictors of mortality in
blood stream infections caused by Klebsiella pneumoniae
carbapenemase‑producing K. pneumoniae: Importance of
combination therapy. Clin Infect Dis 2012;55:943‑50.
36. ZarkotouO, Pournaras S, TseliotiP, Dragoumanos V, Pitiriga V,
Ranellou K, et al. Predictors of mortality in patients with
blood stream infections caused by KPC‑producing Klebsiella
pneumoniae and impact of appropriate antimicrobial treatment.
Clin Microbiol Infect 2011;17:1798‑803.
37. DaikosGL, TsaousiS, TzouvelekisLS, AnyfantisI, PsichogiouM,
Argyropoulou A, et al. Carbapenemase‑producing Klebsiella
pneumoniae blood stream infections: Lowering mortality by
antibiotic combination schemes and the role of carbapenems.
Antimicrob Agents Chemother 2014;58:2322‑8.
38. Schwaber MJ, Carmeli Y. Mortality and delay in effective
therapy associated with extended‑spectrum beta‑lactamase
production in Enterobacteriaceae bacteraemia: A systematic
review and meta‑analysis. J Antimicrob Chemother
2007;60:913‑20.
39. Balkan II, Aygün G, Aydin S, Mutcali SI, Kara Z,
Kuskucu M, et al. Blood stream infections due to OXA‑48‑like
carbapenemase‑producing Enterobacteriaceae: Treatment and
survival. Int J Infect Dis 2014;26:51‑6.
40. Kalanuria AA, Zai W, Mirski M. Ventilator‑associated
pneumonia in the ICU. Crit Care 2014;18:208.
41. Garnacho‑Montero J, Corcia‑Palomo Y, Amaya‑Villar R,
Martin‑Villen L. How to treat VAP due to MDR pathogens in
ICU patients. BMC Infect Dis 2014;14:135.
42. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M.
A retrospective observational study on the efficacy of colistin
by inhalation as compared to parenteral administration for
the treatment of nosocomial pneumonia associated with
multidrug‑resistant Pseudomonas aeruginosa. BMC Infect Dis
2011;11:317.
43. Gu WJ, Wang F, Tang L, Bakker J, Liu JC. Colistin for the
treatment of ventilator‑associated pneumonia caused by
multidrug‑resistant Gram‑negative bacteria: A systematic
review and meta‑analysis. Int J Antimicrob Agents
2014;44:477‑85.
44. Ye JJ, Lin HS, Kuo AJ, Leu HS, Chiang PC, Huang CT, et al.
The clinical implication and prognostic predictors of tigecycline
treatment for pneumonia involving multidrug‑resistant
Acinetobacter baumannii. J Infect 2011;63:351‑61.
45. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, et al.
Effect of sulbactam on infections caused by imipenem‑resistant
Acinetobacter calcoaceticus biotype anitratus. J Infect Dis
1993;167:448‑51.
46. Garnacho‑Montero J, Ortiz‑Leyba C, Jiménez‑Jiménez FJ,
Barrero‑Almodóvar AE, García‑Garmendia J L ,
Bernabeu‑WittelI M, et al. Treatment of multidrug‑resistant
Acinetobacter baumannii v e n t i l a t o r ‑ a s s o c i a t e d
pneumonia (VAP) with intravenous colistin: A comparison
with imipenem‑susceptible VAP. Clin Infect Dis 2003;36:1111‑8.
47. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC.
Tetracyclines for treating multidrug‑resistant Acinetobacter
baumannii ventilator‑associated pneumonia. Intensive Care
Med 2003;29:2072‑6.
48. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of
pan‑drug resistant Acinetobacter baumannii. Scand J Infect Dis
2005;37:195‑9.
49. Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M,
Franchi C, et al. Combined colistin and rifampicin therapy
for carbapenem‑resistant Acinetobacter baumannii infections:
Clinical outcome and adverse events. Clin Microbiol Infect
2005;11:682‑3.
50. Bassetti M, Repetto E, Righi E, Boni S, Diverio M,
Molinari MP, et al. Colistin and rifampicin in the treatment
of multidrug‑resistant Acinetobacter baumannii infections.
J Antimicrob Chemother 2008;61:417‑20.
51. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G.
High‑dose ampicillin‑sulbactam as an alternative treatment
of late‑onset VAP from multidrug‑resistant Acinetobacter
baumannii. Scand J Infect Dis 2007;39:38‑43.
52. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI,
Aydemir S, Bacakoglu F. Is tigecyclin a good choice in the
treatment of multidrug‑resistant Acinetobacter baumannii
pneumonia? J Chemother 2011;23:345‑9.
53. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP,
Massih RC, et al. Epidemiology, clinical characteristics and
outcomes of extensively drug‑resistant Acinetobacter baumannii
infections among solid organ transplant recipients. PLoS One
2012;7:e52349.
54. Durante‑Mangoni E, Signoriello G, Andini R, Mattei A,
De Cristoforo M, Murino P, et al. Colistin and rifampicin
compared with colistin alone for the treatment of serious
infections due to extensively drug‑resistant Acinetobacter
baumannii: A multicenter, randomized clinical trial. Clin Infect
Dis 2013;57:349‑58.
55. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K,
Doganay M. Use of high‑dose IV and aerosolized colistin for the treatment of multidrug‑resistant Acinetobacter baumannii
ventilator‑associated pneumonia: Do we really need this
treatment? J Infect Chemother 2012;18:872‑7.
56. McLaughlin MM, Advincula MR, Malczynski M, Barajas G,
Qi C, Scheetz MH. Quantifying the clinical virulence of
Klebsiella pneumoniae producing carbapenemase Klebsiella
pneumoniae with a Galleria mellonella model and a pilot study
to translate to patient outcomes. BMC Infect Dis 2014;14:31.
57. Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT,
Chen YC, et al. Effectiveness of tigecycline‑based versus
colistin‑based therapy for treatment of pneumonia caused by
multidrug‑resistant Acinetobacter baumannii in a critical setting:
A matched cohort analysis. BMC Infect Dis 2014;14:102.
58. Krol V, Hamid NS, Cunha BA. Neurosurgically related
nosocomial Acinetobacter baumannii meningitis: Report of two
cases and literature review. J Hosp Infect 2009;71:176‑80.
59. Wroblewska MM, Dijkshoorn L, Marchel H, van den
Barselaar M, Swoboda‑Kopec E, van den Broek PJ, et al.
Outbreak of nosocomial meningitis caused by Acinetobacter
baumannii in neurosurgical patients. J Hosp Infect 2004;57:300‑7.
60. Nagaveni S, Rajeshwari H, OliAK, Patil SA, ChandrakanthRK.
Widespread emergence of multidrug resistant Pseudomonas
aeruginosa isolated from CSF samples. Indian J Microbiol
2011;51:2‑7.
61. van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR.
Advances in treatment of bacterial meningitis. Lancet
2012;380:1693‑702.
62. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sadoh S,
Kobayashi T, et al. Pharmacokinetics and protein binding
of linezolid in cerebrospinal fluid and serum in a case of
post‑neurosurgical bacterial meningitis. Scand J Infect Dis
2011;43:982‑5.
63. Di Paolo A, Gori G, Tascini C, Danesi R, Del Tacca M. Clinical
pharmacokinetics of antibacterials in cerebrospinal fluid. Clin
Pharmacokinet 2013;52:511‑42.
64. Rodríguez Guardado A, Blanco A, Asensi V, Pérez F, Rial JC,
Pintado V, et al. Multidrug‑resistant Acinetobacter meningitis
in neurosurgical patients with intraventricular catheters:
Assessment of different treatments. J Antimicrob Chemother
2008;61:908‑13.
65. CascioA, ContiA, Sinardi L, Iaria C, Angileri FF, Stassi G, et al.
Post‑neurosurgical multidrug‑resistant Acinetobacter baumannii
meningitis successfully treated with intrathecal colistin. A new
case and a systematic review of the literature. Int J Infect Dis
2010;14:e572‑9.
66. Imberti R, Cusato M, Accetta G, Marinò V, Procaccio F,
Del Gaudio A, et al. Pharmacokinetics of colistin in
cerebrospinal fluid after intraventricular administration of
colistin methanesulfonate. Antimicrob Agents Chemother
2012;56:4416‑21.
67. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or
intrathecal use of polymyxins in patients with Gram‑negative
meningitis: A systematic review of the available evidence. Int
J Antimicrob Agents 2007;29:9‑25.
68. Khawcharoenporn T, Apisarnthanarak A, Mundy LM.
Intrathecal colistin for drug‑resistant Acinetobacter baumannii
central nervous system infection: A case series and systematic
review. Clin Microbiol Infect 2010;16:888‑94.
69. MarkantonisSL, MarkouN, FousteriM, SakellaridisN, KaratzasS,
Alamanos I, et al. Penetration of colistin into cerebrospinal fluid.
Antimicrob Agents Chemother 2009;53:4907‑10.
70. Karaiskos I, Galani L, Baziaka F, Giamarellou H.
Intraventricular and intrathecal colistin as the last therapeutic
resort for the treatment of multidrug‑resistant and extensively
drug‑resistant Acinetobacter baumannii ventriculitis and
meningitis: A literature review. Int J Antimicrob Agents
2013;41:499‑508.
71. Georges H, Chiche A, Alfandari S, Devos P, Boussekey N,
Leroy O. Adult community‑acquired bacterial meningitis
requiring ICU admission: Epidemiological data, prognosis
factors and adherence to IDSA guidelines. Eur J Clin Microbiol
Infect Dis 2009;28:1317‑25.
72. Rodríguez‑Baño J, Martí S, Soto S, Fernández‑Cuenca F,
Cisneros JM, Pachón J, et al. Biofilm formation in Acinetobacter
baumannii: Associated features and clinical implications. Clin
Microbiol Infect 2008;14:276‑8.
73. Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al.
Management of meningitis due to antibiotic‑resistant Acinetobacter
species. Lancet Infect Dis 2009;9:245‑55.
74. Levison ME, Kaye D. Treatment of complicated urinary tract
infections with an emphasis on drug‑resistant gram‑negative
uropathogens. Curr Infect Dis Rep 2013;15:109‑15.
75. Takeyama K, Kunishima Y, Matsukawa M, Takahashi S,
Hirose T, Kobayashi N, et al. Multidrug‑resistant Pseudomonas
aeruginosa isolated from the urine of patients with urinary tract
infection. J Infect Chemother 2002;8:59‑63.
76. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne
WM Jr, Ritchie DJ. Treatment and clinical outcomes of urinary
tract infections caused by KPC‑producing Enterobacteriaceae
in a retrospective cohort. Clin Ther 2012;34:1314‑23.
77. Volkow‑Fernández P, Rodríguez CF, Cornejo‑Juárez P.
Intravesical colistin irrigation to treat multidrug‑resistant
Acinetobacter baumannii urinary tract infection: A case report.
J Med Case Rep 2012;6:426.
78. Rafailidis PI, Falagas ME. Options for treating
carbapenem‑resistant Enterobacteriaceae. Curr Opin Infect
Dis 2014;27:479‑83.
79. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K,
Kapaskelis AM, Falagas ME. Aerosolized colistin for the
treatment of nosocomial pneumonia due to multidrug‑resistant
Gram‑negative bacteria in patients without cystic fibrosis. Crit
Care 2005;9:R53‑9
)